CRBP Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $1.40 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.2% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics to treat rare, life-threating inflammatory-fibrotic diseases.
Sector
Healthcare
Industry
Biotechnology